Neurolentech is a spinoff of ISTA (Institute of Science and Technology Austria) focused on personalized medicine for neurodevelopmental disorders. The company is developing and characterizing libraries of patient-derived neuronal cells, and will leverage this unique resource for the development of novel therapeutics to tackle severe forms of autism and epilepsy.

xista team

profile photo
Alexander Schwartz

Medicine has made great strides forward in recent decades by tackling easily diagnosable diseases and conditions that affect large patient groups. This broad-brush approach makes sense in the context of the traditional pharma industry model, but it bypasses the needs of the patients with so-called rare diseases, although they amount to 1 in 17 of the European population. Even if such patients receive an accurate diagnosis (which many do not, due to lack of awareness or reliable diagnostic methods), there are often no effective therapies available to them.

This is where innovators like the founders of Neurolentech come into play. Neurolentech is a spinoff of the Institute of Science and Technology Austria, whose area of expertise is in neurodevelopmental disorders (NDDs), particularly autism spectrum disorders and epilepsy. While these conditions are not rare as such (affecting at least 1% of the population), they are actually very heterogeneous disorders with diverse causes that are lumped together under a single diagnosis. When the diversity of the patient population is considered, it is not surprising that no effective pharmaceutical drugs have been developed to address the core symptoms of autism, or that there are many patients who do not respond well to existing anti-epileptics.

Neurolentech’s approach is to characterize neuronal cells from individual patients in a highly comprehensive manner, delivering rich omics data, morphology and electrophysiology. By analyzing these data it will become possible to enhance understanding of the disrupted molecular pathways in patient subgroups, leading  to identification of novel drug targets, and ultimately to new therapeutics to test in the clinic.

The Neurolentech team has unique sector expertise, allowing them to execute on ambitious plans to address unmet patient needs.

Pitch your idea

Investment process

1. Share your Information

Use the form to tell us about your startup. Our team will review the details provided and will get back to you as soon as possible. If you meet the required criteria, we’ll plan together the next steps of your funding journey.

2. Start the financing process

We start by inviting you to a meeting and gather more information relevant to conducting a due diligence process, evaluating your business plans, growth strategy, and financial forecasts. Together, we analyze and determine the essential details and deal structure to meet your unique financing requirements.

3. Raise capital

If we invest, we will likely lead your funding round and will help you to fill your round and guide you through the process. From round preparations to execution, our team is here to support you, ensuring a smooth and successful experience.

4. Go beyond financing

We will be your partner in everything you encounter while executing your plans. We offer continuous support and guidance as we firmly believe long-term succes is a shared mission.